Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2015 May;74(5):442–452. doi: 10.1097/NEN.0000000000000188

Figure 2.

Figure 2

Effect of CDKN2A loss on overall survival of histologically classified lower grade (World Health Organization II-III) gliomas. (A–D) CDKN2A loss was associated with worse overall survival in lower grade gliomas not stratified by histology (A) and in astrocytomas (B), but not in oligodendrogliomas (C) or oligoastrocytomas (D).

HHS Vulnerability Disclosure